|Year : 2019 | Volume
| Issue : 3 | Page : 363-368
Evaluation of relationship between serum homocysteine and Vitamin B12 levels in oral submucous fibrosis patients using chemiluminescence immunoassay
Mukta Vijaykumar Vanjani, Rashmi G S Phulari, Rajendrasinh Rathore
Department of Oral and Maxillofacial Pathology and Microbiology, Manubhai Patel Dental College and Hospital, Vadodara, Gujarat, India
|Date of Submission||08-Jan-2019|
|Date of Acceptance||27-Jun-2019|
|Date of Web Publication||19-Dec-2019|
Mukta Vijaykumar Vanjani
C – 5, Bansuri Apartment, Pashabhai Park, Race Course, Vadodara - 390 007, Gujarat
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Serum homocysteine (Hcy), a nonessential amino acid, is considered as a helpful indicator of vitamin status for its strong correlation with Vitamin B12. Although Hcy levels in oral submucous fibrosis (OSMF) have been studied, the relationship between Hcy and Vitamin B12 has not been studied yet. This study is the first one to compare and correlate the levels of serum Hcy and Vitamin B12 in OSMF patients.
Materials and Methods: The study group comprised 60 patients. Serum Hcy and Vitamin B12 estimation were done by chemiluminescence immunoassay. These levels in OSMF patients were compared and correlated with corresponding levels in healthy controls.
Results: Hcy levels were elevated in OSMF and were found to be statistically significant (P = 0.014) as compared to healthy controls. On the contrary, although Vitamin B12 levels were found to be higher in healthy controls, the difference was statistically nonsignificant (P = 0.657). A significant correlation was found (P = 0.01) between Hcy and Vitamin B12 in both groups, i.e., decreased Vitamin B12 levels led to elevated Hcy levels but vice versa was not found. No correlation was found between levels of Hcy and the severity of OSMF (P = 0.806).
Conclusion: Chronic inflammation in OSMF leads to hyperhomocysteinemia, which may also be seen in cases of Vitamin B12 deficiency and certain systemic disorders. Thus, while serum Hcy could be used as biomarker for OSMF, Vitamin B12 deficiency and certain systemic disorders should be ruled out.
Keywords: Chemiluminescence immunoassay, homocysteine, oral submucous fibrosis, serum, Vitamin B12
|How to cite this article:|
Vanjani MV, Phulari RG, Rathore R. Evaluation of relationship between serum homocysteine and Vitamin B12 levels in oral submucous fibrosis patients using chemiluminescence immunoassay. J Oral Maxillofac Pathol 2019;23:363-8
|How to cite this URL:|
Vanjani MV, Phulari RG, Rathore R. Evaluation of relationship between serum homocysteine and Vitamin B12 levels in oral submucous fibrosis patients using chemiluminescence immunoassay. J Oral Maxillofac Pathol [serial online] 2019 [cited 2020 Jan 18];23:363-8. Available from: http://www.jomfp.in/text.asp?2019/23/3/363/273510
| Introduction|| |
Oral submucous fibrosis (OSMF), first described by Schwartz in 1952, is a collagen metabolic disorder and a chronic premalignant condition of the oral mucosa. Pindborg and Sirsat defined OSMF as “an insidious, chronic disease affecting any part of the oral cavity and sometimes the pharynx. Although occasionally preceded by and/or associated with vesicle formation, it is always associated with juxtaepithelial inflammatory reaction followed by fibroelastic change of the lamina propria, with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus and inability to eat.”
Amino acids and their derivatives can be useful disease markers as they reflect the protein metabolism, problems related to dietary uptake and aid in understanding the metabolic derangements that occur during the pathological processes induced by the potentially malignant disorders (PMDs).
Homocysteine (Hcy) found in humans is a nonessential, sulfur-containing amino acid with a molecular weight of 135.2 Da. Hcy is not contained in the protein or DNA, but it is a metabolic intermediary derived from the essential sulfur-containing amino acid – methionine, during its metabolism in the methionine cycle. In plasma, 80% of Hcy is protein bound.,
Hcy is a valuable indicator for factors such as exercise, coffee drinking, smoking, vitamins and cholesterol. Only a handful of studies have shown an association of serum Hcy in PMDs of the oral cavity and elsewhere, with a few reports showing elevated Hcy levels.,,
Hence, the present study was undertaken to evaluate the serum levels of Hcy and Vitamin B12 in OSMF patients as compared to healthy controls. This study also aimed at assessing the correlation between the levels of serum Hcy and Vitamin B12 in both the groups and to find if there is any correlation between the levels of serum Hcy and the severity of OSMF.
| Materials and Methods|| |
This comparative study was carried out in the Department of Oral and Maxillofacial Pathology and Microbiology for a period of 1 year, after obtaining approval from the Institutional Ethical Committee and Review Board (MPDC_113/OPATH-27/17).
The study group comprised 60 participants and was divided into two groups. Group 1 comprised 30 patients, clinically diagnosed with OSMF, and grading was done according to the criteria given by Ranganathan et al. Group 2 comprised 30 healthy controls.
With regard to the first group, gender matching was done in the second group to avoid the bias. A written informed consent was taken from each of the patient before enrolling in the study.
Diagnostic criteria used for selection of cases
Inclusion criteria included patients between the age range of 20 and 60 years and only those patients who gave consent to participate. Thirty patients clinically diagnosed with OSMF and 30 healthy individuals without any habit of areca nut chewing and tobacco were included in the study. Diseases such as diabetes mellitus, osteoporosis, coronary artery disease, Parkinson's disease, smoking, alcoholism, peripheral vasculitis, deep-vein thrombosis and Alzheimer's disease are known to alter the serum Hcy profile. Hence, patients suffering from such diseases were excluded from the study. Furthermore, patients undergoing any drug therapy capable of altering Hcy levels were not included.
Venous blood samples were collected with aseptic precautions using spirit-soaked cotton. A volume of 5 ml of blood was drawn from the antecubital vein (cephalic vein) using disposable syringe, and without any delay, the blood was transferred to the vacutainer. Cold centrifugation (15–17° C) at 4000 rpm was done immediately to separate the serum from the cells, and this separated serum was then subjected to chemiluminescence immunoassay (CLIA) for the estimation of Hcy and Vitamin B12.
This immunoassay is based on the specific binding of an antibody toward the Hcy enzyme conversion product, S-adenosyl-Hcy. The quantification thus achieved is through construction of a standard curve with multiple known concentrations of Hcy calibrators.
The statistical analysis was done using Statistical Package for Social Science version 16.0 Software (SPSS Inc., Chicago, IL, USA) by setting the significance value at P < 0.05. The difference between the serum Hcy levels in OSMF patients and healthy controls was estimated using independent t-test, whereas for Vitamin B12, the difference was estimated using Mann–Whitney U-test. Furthermore, Pearson's correlation test was used to find the correlation between serum Hcy and Vitamin B12 in OSMF patients and healthy controls and also to find the correlation between the levels of serum Hcy and the severity of OSMF.
| Results|| |
A total of 60 patients were taken which included 30 clinically diagnosed OSMF cases and 30 healthy controls. Patients between the age range of 20 and 60 years participated in the study. Furthermore, gender matching was done to avoid the bias.
For adults, the biological reference range of serum Hcy is 5–15 μmol/L, whereas for Vitamin B12, the range is 200–900 pg/ml.
In our study, the mean Hcy levels were elevated in OSMF (46.6 ± 26.9 μmol/L) and were found to be statistically significant (P = 0.014) as compared to healthy controls (31.1 ± 20.4 μmol/L) [Table 1].
|Table 1: Difference between homocysteine levels in oral submucous fibrosis patients and healthy controls|
Click here to view
On the contrary, although mean Vitamin B12 levels were found to be higher in healthy controls (187.6 ± 145.5 pg/ml) as compared to OSMF (141.3 ± 89.6 pg/ml), the difference was statistically nonsignificant (P = 0.657) [Table 2].
|Table 2: Difference between vitamin B12 levels in oral submucous fibrosis patients and healthy controls|
Click here to view
Furthermore, a significant correlation was found (P = 0.01) between serum Hcy and Vitamin B12 in both the groups [Table 3], i.e., decreased Vitamin B12 levels led to elevated Hcy levels, but vice– versa was not found; that means, there was a one-way inverse proportional relationship.
|Table 3: Correlation between serum homocysteine and Vitamin B12 in oral submucous fibrosis patients and healthy controls|
Click here to view
However, no correlation (P = 0.806) was found between the levels of serum Hcy and the severity of OSMF [Table 4] and [Table 5].
|Table 4: Mean homocysteine levels of different grades of oral submucous fibrosis|
Click here to view
|Table 5: Correlation between the levels of serum homocysteine and severity of oral submucous fibrosis|
Click here to view
| Discussion|| |
OSMF, a PMD, has a multifactorial etiology although chewing of areca nut and tobacco are chiefly associated with this disorder in the South East Asian populations. It causes significant morbidity and has a malignant transformation rate of about 7%–13%. The nutritional deficiencies such as iron, folates, Vitamin B12 and Vitamin B6 might not play a primary role in the etiopathogenesis, but it could synergize the symptomatology by contributing to epithelial atrophy.,
OSMF patients either present with the complaint of reduced mouth opening or with burning sensation, which results in difficulty in consumption of normal diet leading to poor nutrition. Deficiency of iron and Vitamin B complex, other trace elements and lipids, could possibly initiate anemia, alter the cell-mediated immunity and generate free radicals and reactive oxygen species from the peroxidation of lipids and induce DNA damage., The psychological stress due to burning, pain and reduced mouth opening may lead to reduced intake of food, leading to the nutritional deficiency, consequently leading to an increase in Hcy levels.
Elevated Hcy concentrations are also associated with specific pathological conditions, including cancer development, autoimmune diseases, vascular dysfunction and neurodegenerative disease. Moreover, Vitamin B12, folate and B6 are needed in the Hcy remethylation pathway and transsulfuration pathway.
In earlier studies conducted by Goel et al. in 2014 and Jaganath et al. in 2016, Hcy was determined using high-performance liquid chromatography; but in the present research, CLIA was used, which is much more advanced and sophisticated method used nowadays.
In our study, the mean Hcy levels were elevated in OSMF (46.6 ± 26.9 μmol/L) and were found to be statistically significant (P = 0.014) as compared to healthy controls (31.1 ± 20.4 μmol/L). This is in accordance with the studies conducted by Bais et al. in 2013 and Narang et al. in 2014 on OSMF patients. In these studies, no healthy controls were taken, and it was observed that serum Hcy level was increased in all the patients irrespective of gender and age.
Moreover, the mean Vitamin B12 levels in our study were found to be higher in healthy controls (187.6 ± 145.5 pg/ml) as compared to OSMF (141.3 ± 89.6 pg/ml); but, the difference was statistically nonsignificant (P = 0.657).
These results obtained are in congruence with the study done by Chen et al. in 2015; in which the Hcy concentrations and Vitamin B12 levels of oral lichen planus (OLP) patients were measured and compared with the corresponding levels in healthy controls. OLP patients showed a significantly higher mean Hcy level than healthy controls and a lower mean Vitamin B12 level when compared to healthy controls. It was found in their research that OLP patients had a significantly higher frequency of Vitamin B12 deficiency and had an abnormally elevated Hcy level than the control group.
A research conducted by Nacci et al. in 2008 showed decreased Vitamin B12 levels and elevated Hcy levels in patients with laryngeal cancer. Furthermore, Rasool et al. in 2012 did a study and demonstrated an inverse relationship between serum levels of Vitamin B12 and Hcy in patients with functional dyspepsia. Likewise, Sun et al. in 2012 and Lin et al. in 2013 evaluated an intimate association of deficiency of Vitamin B12 and high blood Hcy level in patients with atrophic glossitis and burning mouth syndrome, respectively.
Another similar study conducted by Wang et al. in 2014 also showed deficiency of Vitamin B12 and abnormally high blood Hcy levels in patients with antithyroid autoantibodies. Similar results were also found in the researches conducted by Sun et al. in 2015 and Narang et al. in 2016 in patients with recurrent aphthous stomatitis and metabolic syndrome, respectively.
According to the current literature search, the relationship between serum Hcy and Vitamin B12 in OSMF has not been studied till now; therefore, this study was undertaken to compare and correlate the levels of serum Hcy and Vitamin B12 in OSMF.
In this study, a significant correlation (P = 0.01) was obtained between serum Hcy and Vitamin B12 in both the groups, i.e., decreased Vitamin B12 levels led to elevated Hcy levels, but vice– versa was not found; that means, there was a one-way inverse proportional relationship.
This proves that Vitamin B12 deficiency can indicate hyperhomocysteinemia (elevated Hcy levels), but hyperhomocysteinemia does not necessarily indicate Vitamin B12 deficiency. Elevated serum Hcy levels can be associated with chromosome damage even in the absence of Vitamin B12 deficiency. Moreover, hyperhomocysteinemia can indicate any systemic disease, especially vascular disease or any pathological condition.
Besides, due to skewed distribution of data, our study showed no correlation (P = 0.806) between the levels of serum Hcy and the severity of OSMF, which is in consonance to the studies done by Bais et al. in 2013 and Narang et al. in 2014, in which no statistically significant correlation was found when comparing Hcy levels with the clinical staging of OSMF.
Hcy levels >15 μmol/L bring about a copper-dependent oxidative damage to cellular and isolated DNA, as seen in our study. In patients with betel quid chewing habit, the betel nut within the quid acts as a source of high levels of soluble copper, which gets acted on by lysyl oxidase, a copper-dependent enzyme, which is vital for collagen synthesis and cross-linkage of fibers in OSMF. Thus, the increased availability of copper and Hcy doubles the chance of DNA damage.
However, the mechanism of chromosomal damage by Vitamin B12 deficiency might be due to reduced methylation of uracil to thymine, leading to subsequent incorporation of uracil into human DNA.
| Conclusion|| |
OSMF is a chronic inflammatory disease which results in oxidative stress (oxidative DNA damage) leading to hyperhomocysteinemia which in turn exerts its deleterious effects through induction of acute and chronic inflammation pathways such as endothelial adhesion and leukocyte adhesion.
Thus, chronic inflammation in OSMF leads to hyperhomocysteinemia, which can be used as a potential biological marker for the early detection and treatment of the disease.
However, hyperhomocysteinemia may also be seen in cases of Vitamin B12 deficiency and certain systemic disorders such as cardiovascular disease. Thus, while serum Hcy levels could be used as biomarker for OSMF, Vitamin B12 deficiency and certain systemic disorders should be ruled out.
The present research revealed that OSMF patients have significantly elevated Hcy concentrations and decreased Vitamin B12 levels as compared to healthy controls. Additionally, an interesting correlation was found between serum Hcy and Vitamin B12, that is, a one-way inverse proportional relationship exists between serum Hcy and Vitamin B12.
Furthermore, no correlation was found between the levels of serum Hcy and the severity of OSMF. Hence, studies with equal sample size are needed to reinforce this finding of our study.
I, Dr. Mukta V. Vanjani, would like to pay regard to my Father, Dr. Vijay T. Vanjani for his immense encouragement and financial support, without whom this research would not have been possible. Also I would like to show my heartfelt gratitude to Dr. Reema Agrawal, Senior Lecturer in the Department of Public Health and Community Dentistry, M.P.D.C, for sharing her pearls of wisdom with me during the course of this research. Last but not the least, the words are not enough to express my special thanks to Dr. Harsukh and Dr. Tushar Toprani of Toprani Advanced Lab Systems, Vadodara, Gujarat, where serum homocysteine and Vitamin B12 were determined using chemiluminescence immunoassay.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Schwartz J. Atrophia idiopathica (tropica) mucosae oris. In: Proceedings of the 11th
International Dental Congress, London, 1952 (cited by Sirsat and Khanolkar). Indian J Med Sci1962;16:185-97.
Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 1966;22:764-79.
Goel R, Sukumaran G, Chandrasekhar T, Ramani P, Sherlin HJ, Natesan A, et al.
Amino acid profile in oral submucous fibrosis: A high performance liquid chromatography (HPLC) study. J Clin Diagn Res 2014;8:ZC44-8.
Larkin M. Kilmer McCully: Pioneer of the homocysteine theory. Lancet 1998;352:1364.
Klee GG. Cobalamin and folate evaluation: Measurement of methylmalonic acid and homocysteine vs. Vitamin B(12) and folate. Clin Chem 2000;46:1277-83.
Bais PS, Chauhan P, Mohan S. An evaluation of serum homocysteine as a biological marker in oral sub mucous fibrosis in a Western setting of Uttar Pradesh, India. IOSR J Dent Med Sci 2013;9:66-9.
Narang D, Shishodiya S, Sur J, Khan NF. Estimation of serum homocysteine: As a diagnostic marker of oral submucous fibrosis. Carcinog Mutagen 2014;5:187-9.
Chen HM, Wang YP, Chang JY, Wu YC, Cheng SJ, Sun A. Significant association of deficiencies of hemoglobin, iron, folic acid, and Vitamin B12 and high homocysteine level with oral lichen planus. J Formos Med Assoc 2015;114:124-9.
Ranganathan K, Umadevi M, Elizabeth J, Arun B, Rooban T, Visawanathan R. Mouth opening, cheek flexibility and tongue protrusion parameters of 800 normal patients in Chennai, South India – A baseline study to enable assessment of alterations in oral submucous fibrosis. J Indian Dent Assoc 2001;72:78-80.
Auluck A, Rosin MP, Zhang L, Sumanth KN. Oral submucous fibrosis, a clinically benign but potentially malignant disease: Report of 3 cases and review of the literature. J Can Dent Assoc 2008;74:735-40.
Rajendran R. Oral submucous fibrosis: Etiology, pathogenesis, and future research. Bull World Health Organ 1994;72:985-96.
Dyavanagoudar SN. Oral submucous fibrosis: Review on etiopathogenesis. J Cancer Sci Ther 2009;1:72-7.
Ahmad MS, Ali SA, Ali AS, Chaubey KK. Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers of Patna, Bihar, India. J Indian Soc Pedod Prev Dent 2006;24:84-9.
] [Full text]
Patel PS, Shah MH, Jha FP, Raval GN, Rawal RM, Patel MM, et al.
Alterations in plasma lipid profile patterns in head and neck cancer and oral precancerous conditions. Indian J Cancer 2004;41:25-31.
] [Full text]
Sun A, Lin HP, Wang YP, Chiang CP. Significant association of deficiency of hemoglobin, iron and Vitamin B12, high homocysteine level, and gastric parietal cell antibody positivity with atrophic glossitis. J Oral Pathol Med 2012;41:500-4.
Schalinske KL, Smazal AL. Homocysteine imbalance: A pathological metabolic marker. Adv Nutr 2012;3:755-62.
Jaganath SS, Kaveri H, Okade A. Determination of plasma homocysteine levels in oral submucous fibrosis & oral squamous cell carcinoma using high performance liquid chromatography and its plausibility as a potential biomarker. World J Pharm Res 2016;5:1125-41.
Nacci A, Dallan I, Bruschini L, Traino AC, Panicucci E, Bruschini P, et al.
Plasma homocysteine, folate, and Vitamin B12 levels in patients with laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008;134:1328-33.
Rasool S, Abid S, Iqbal MP, Mehboobali N, Haider G, Jafri W. Relationship between Vitamin B12, folate and homocysteine levels and H. Pylori infection in patients with functional dyspepsia: A cross-section study. BMC Res Notes 2012;5:206.
Lin HP, Wang YP, Chen HM, Kuo YS, Lang MJ, Sun A. Significant association of hematinic deficiencies and high blood homocysteine levels with burning mouth syndrome. J Formos Med Assoc 2013;112:319-25.
Wang YP, Lin HP, Chen HM, Kuo YS, Lang MJ, Sun A. Hemoglobin, iron, and Vitamin B12 deficiencies and high blood homocysteine levels in patients with anti-thyroid autoantibodies. J Formos Med Assoc 2014;113:155-60.
Sun A, Chen HM, Cheng SJ, Wang YP, Chang JY, Wu YC, et al.
Significant association of deficiencies of hemoglobin, iron, Vitamin B12, and folic acid and high homocysteine level with recurrent aphthous stomatitis. J Oral Pathol Med 2015;44:300-5.
Narang M, Singh M, Dange S. Serum homocysteine, Vitamin B12 and folic acid levels in patients with metabolic syndrome. J Assoc Physicians India 2016;64:22-6.
Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol 2006;42:561-8.
Ames BN. Micronutrient deficiencies. A major cause of DNA damage. Ann N Y Acad Sci 1999;889:87-106.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]